Infusion of Apomorphine: Long-term Safety Study

Inclusion Criteria: * Advanced idiopathic PD consistent with UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria * Overall motor control is unsatisfactory in the opinion of the Investigator and subject despite optimized treatment with available therapies, which must include a stable regimen of daily maintenance levodopa (or levodopa/carbidopa), and at least one of the following other classes of therapies: * Dopamine agonists (note: APOKYN intermittent injection is not to be considered here) * Monoamine oxidase B \[MAO B\] inhibitors * Catechol-O-methyltransferase (COMT) inhibitors * Deep brain stimulation (DBS) * Levodopa/carbidopa intestinal gel surgery (Duopa, Duodopa) * Other - amantadine at doses of up to 400 mg per day) * Experiences "off" periods averaging ≥3.0 hours per waking day * Other criteria will be discussed in detail with potential subjects by site Investigator Exclusion Criteria: * Planned surgical intervention for the treatment of Parkinson's disease during participation in the study * History of hypersensitivity to apomorphine hydrochloride or any of the ingredients of APOKYN PFS, including sodium metabisulfite * Known, suspected, or planned pregnancy or lactation. * Recent history (within the previous 12 months) of alcohol or substance abuse * History of impulsive/compulsive behaviors primarily associated with the use of dopamine agonists * History of previously treated or current diagnosis of malignant melanoma * Exhibits certain signs and symptoms of cardiovascular disease * Other criteria will be discussed in detail with potential subjects by site Investigator